Clinical Trial

COVID-19 Reactogenicity

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 4, 2026 (before its estimated June 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-01.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-03-02
Trial Details
NCT Number NCT07051031
Lead Sponsor Marcel Curlin
Conditions COVID-19
Enrollment 1,000 participants
Start Date 2025-10-01
Primary Completion 2026-06-14 (estimated)
Study Completion 2026-06-14 (estimated)
Updated on ClinicalTrials.gov 2026-03-04